Puma Bio Falls as Cancer Drug Trial Results Seen as Murky
This article is for subscribers only.
Puma Biotechnology Inc. fell the most in almost a year after reporting results from a breast-cancer drug trial that disappointed investors.
The drug, neratinib, improved the rate of patients free of the disease after two years compared with a placebo, based on a trial of 2,821 patients who tested positive for a protein called HER2 and had already gotten initial treatment. However, the rate of disease-free survival with neratinib, at 93.9 percent, was